Cash Dividends, Conference Presentations, Pricing of Offering, and Senate's Statement - Analyst Notes on Universal Health Services, AmSurg, Spectranetics, Edwards Lifesciences and Spherix

NEW YORK, June 3, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Universal Health Services, Inc. (NYSE: UHS), AmSurg Corp (NASDAQ: AMSG), The Spectranetics Corporation (NASDAQ: SPNC), Edwards Lifesciences Corp (NYSE: EW) and Spherix Inc (NASDAQ: SPEX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3243-100free.

--
Universal Health Services, Inc. Analyst Notes
On May 21, 2014, Universal Health Services, Inc. announced that its Board of Directors has agreed to pay a cash dividend of $0.05 per share. According to the Company, the dividend will be paid on June 16, 2014, to shareholders of record as of June 2, 2014. The full analyst notes on Universal Health Services are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/UHS/report.pdf

--
AmSurg Corp Analyst Notes
On May 28, 2014, AmSurg Corp (AmSurg) announced that it's President and CEO, Christopher A. Holden, and Executive Vice President and CFO, Claire M. Gulmi, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014, at 10:30 a.m. ET (9:30 a.m. CT), in New York City. The Company stated the live audio webcast and replay of the presentation will be available on the investors section of the Company's website. AmSurg added that a webcast replay will also be available for 30 days. The full analyst notes on AmSurg are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/AMSG/report.pdf

--
The Spectranetics Corporation Analyst Notes
On May 29, 2014, The Spectranetics Corporation (Spectranetics) announced the pricing of its $200 million aggregate principal amount offering of its 2.625% convertible Senior Notes due 2034, in an underwritten public offering. Spectranetics stated that it has granted the underwriter of the notes a 30-day option to purchase up to an additional $30 million aggregate principal amount of the notes. The Company stated that the offering is expected to close on June 3, 2014, subject to the satisfaction of customary closing conditions. According to Spectranetics, the notes will accumulate interest at a fixed rate of 2.625% per year, payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2014. The Company informed that the net proceeds of this offering is planned to be used for the funding the proposed acquisition of AngioScore Inc. The full analyst notes on Spectranetics are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/SPNC/report.pdf

--
Edwards Lifesciences Corp Analyst Notes
On May 29, 2014, Edwards Lifesciences Corp (Edwards Lifesciences) announced that its CFO, Scott B. Ullem will present at the Jefferies Global Healthcare Conference on June 4, 2014, at 11:30 a.m. ET, in New York, and at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10, 2014, at 7:00 p.m. ET, in Rancho Palos Verdes. Meanwhile, Edwards Lifesciences' Chairman and CEO, Michael A. Mussallem, will present at the William Blair 34th Annual Growth Stock Conference on June 12, 2014, at 11:00 a.m. ET, in Chicago. The Company stated that live webcasts of the presentations and archive of the same will be available at the Investors section of Edwards Lifesciences' website. The full analyst notes on Edwards Lifesciences are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/EW/report.pdf

--
Spherix Inc Analyst Notes
On May 27, 2014, Spherix Inc (Spherix) notified that the United States Senate and Senate Judiciary Committee Chairman, Patrick Leahy, removed the patent reform bill from the committee's calendar. Citing Senator Leahy, the Company reported that the reason behind this action is the lack of broad bipartisan support for the bill, and the fact that many of the proposals would overly burden legitimate patent holders who employ thousands of Americans. Anthony Hayes, CEO of Spherix, said "The removal of this bill from the Senate Judiciary Committee schedule should remove some of the uncertainty which has been clouding our industry. Spherix is committed to responsibly protecting the patents it owns, and we remain eager to work with companies large and small to reach fair agreements." The full analyst notes on Spherix are available to download free of charge at:

http://www.analystsreview.com/Jun-03-2014/SPEX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED